Brief: Janux Therapeutics Announces Development Candidate Nomination Under Bristol Myers Squibb Collaboration
01/04/2026 14:12
April 1 (Reuters) - Janux Therapeutics Inc JANX.O: JANUX THERAPEUTICS ANNOUNCES DEVELOPMENT CANDIDATE NOMINATION UNDER BRISTOL MYERS SQUIBB COLLABORATION, TRIGGERING $35 MILLION MILESTONE PAYMENT JANUX THERAPEUTICS INC - TO CONDUCT PRECLINICAL DEVELOPMENT; BRISTOL MYERS SQUIBB TO LEAD CLINICAL DEVELOPMENT AND COMMERCIALIZATION JANUX THERAPEUTICS INC - TO SUPPORT BRISTOL MYERS SQUIBB THROUGH FIRST PHASE 1 CLINICAL STUDY JANUX THERAPEUTICS INC - ELIGIBLE FOR ADDITIONAL MILESTONE PAYMENTS AND TIERED ROYALTIES ON GLOBAL SALES Source text: ID:nBwbTfB42a Further company coverage: JANX.O ((Reuters.Briefs@thomsonreuters.com;))